全球防回流裝置市場：市場規模、佔有率和趨勢分析（2022-2028）

2025年全球防回流裝置市場規模約1.99億美元。預計到2032年，該市場規模將超過5.67億美元，年複合成長率為16.2%。

本報告涵蓋了基於手術的胃食道逆流症 (GERD) 器械治療方法，包括經口無切口腹腔鏡手術 (TIF)、經食道射頻消融術 (TEF) 和 LINX 逆流管理系統。報告量化了銷售量、平均售價 (ASP)、市場價值、成長率和企業市場占有率，並分析了市場促進因素和限制因素、近期併購活動以及技術趨勢。報告提供截至 2022 年的歷史數據，並預測至 2032 年。

本次調查範圍反映了隨著人們對胃食道逆流症 (GERD) 的認知不斷提高、證據不斷增加以及患者偏好轉向持久緩解症狀和可預測康復的背景下，醫院和專科中心的醫療保健提供者如何評估基於器械的 GERD 干預措施與藥物治療和腹腔鏡手術的比較。

市場概覽

抗逆流裝置透過增強胃食道連接屏障或重塑下食道括約肌來治療持續性胃食道逆流症。這些治療方法為尋求長期質子幫浦阻斷劑治療替代方案或儘管接受藥物治療但症狀仍持續存在的患者提供了選擇。

三大因素推動了成長。首先，主要廠商針對醫師所進行的定向教育和病患行銷提高了產品認知度。隨著越來越多的醫療中心採用經食道瘺（TIF）、射頻消融和磁增強等技術，手術操作熟練度不斷提高，轉診途徑途徑也日益成熟。其次，人們對長期使用質子幫浦抑制劑（PPI）的擔憂日益加劇。研究表明，長期使用PPI與低鎂血症和骨折風險有關，這促使許多患者和醫生重新評估其長期用藥方案。第三，肥胖症的盛行率持續上升，而中央肥胖與胃食道逆流症（GERD）症狀加重以及僅靠生活方式干涉難以控制密切相關。這些因素共同導致了器械治療諮詢量的穩定成長和目標市場的擴大。

不同機構的實施模式各不相同。大學附屬醫院和大型胃腸病中心通常會建立結構化的反流治療項目，包括治療前評估、標準化的患者篩選和協調的追蹤。社區中心則傾向於專注於一到兩種符合當地技術和患者需求的治療方法，並逐步擴大規模。無論在何種情況下，患者篩選都至關重要。臨床醫師會根據症狀嚴重、解剖結構、是否存在食道裂孔疝氣及其大小、胃腸動力狀態以及藥物反應的全面評估，指導患者選擇最適合的治療方案。

價格和價值動態反映了設備初始成本與後續效益之間的平衡。醫療服務提供者重視手術成功率、症狀緩解的持久性、再次手術率以及減少常規藥物使用的能力。支付者和綜合醫療系統則重視總醫療成本、住院時長以及避免併發症。隨著證據的累積和編碼規範的完善，預計2025年至2032年間，市場將持續成長。

市場促進因素

提高產品認知度

主要企業持續不斷的市場推廣和教育活動正在提高外科醫生、胃腸病學家和患者對反流預防裝置的認知。同行評審的出版物、研討會和指導計畫正在提升反流預防裝置的知名度和信譽度。隨著認知度的提高，越來越多對長期藥物治療不滿意並希望尋求手術解決方案的患者開始接受包括經食道逆流裝置（TIF）、射頻消融術和磁增強術在內的治療方案。外科醫師對TIF的熟悉程度越高，就越能提高手術準備度，並減少手術推廣的障礙。

PPI藥物的副作用

質子幫浦抑制劑（PPI）仍是治療胃食道逆流（GERD）的第一線藥物，但長期使用的擔憂影響著治療決策。長期使用與血清鎂水平降低有關，這可能促使心律不整、肌肉痙攣和癲癇發作。高劑量使用與骨質疏鬆症和骨折風險增加有關，包括腕部、脊椎和髖部骨折。這些安全隱患並非否定PPI的作用，而是鼓勵醫病共用決定用藥時長和替代藥物。隨著越來越多的患者尋求持久的症狀控制，而不是依賴長期藥物治療，PPI的需求正在增加。

肥胖症日益嚴重

中央肥胖與胃食道逆流症（GERD）症狀的嚴重程度之間有顯著相關性。隨著全球肥胖率的上升，頻繁逆流、夜間症狀以及藥物治療效果不佳的患者數量也在增加。已在處理肥胖相關併發症的醫療機構正在擴大基於器械的GERD治療的轉診途徑。隨著器械可靠性的提高，部分新增需求正從慢性藥物治療轉向介入治療，從而推動了整體市場成長。

證據和工作流程成熟度

臨床規範在病患選擇、麻醉、設備選用和追蹤等方面不斷改進。越來越多的中心正在規範術前檢查並採用一致的患者報告結局指標。這有助於更精準的病例選擇、更可預測的治療結果以及更高的患者滿意度。隨著工作流程的日益穩定，各中心也更願意投資於員工培訓和設備支持，加速了這些規範的推廣應用。

市場限制

競爭產品

儘管人們的擔憂日益加劇，但質子幫浦抑制劑（PPI）對許多患者而言仍然有效且易於取得。學名藥降低了患者的自付費用，並有助於維持患者的用藥依從性。新的製劑和給藥策略可以減少突破性症狀，從而延緩或取代器械治療。如果新型藥物能夠改善無反應患者的療效，則器械治療的普及可能會受到抑制，尤其是在對成本較為敏感的市場，因為在這些市場中，支付方通常要求在核准手術前最佳化藥物治療方案。

患者的不適感和期望

所有植入和能量療法都存在手術風險和恢復期的考量。部分患者在植入或能量治療後會出現吞嚥困難、腹脹和胸部不適。吞嚥困難和飲食調整可能會影響患者早期的滿意度。少數情況下，需要取出植入裝置。此外，術後可能出現持續性症狀以及需要繼續每日服藥，這些因素可能會降低患者完全擺脫藥物依賴的慾望。

後續用藥

部分患者在接受器械治療後仍需每日服用抑酸藥物，儘管劑量較低或服用頻率降低。對於注重性價比的支付者和患者而言，這縮小了單純藥物治療與器械治療合併藥物治療之間的差距。管理患者預期並就實際療效達成共識至關重要。溝通不良會促使轉換率低和口碑不佳。

範圍和採購限制

編碼的清晰度和範圍因地區而異。在報銷途徑分散的市場中，醫院面臨著許多行政障礙，阻礙了它們對相關項目的投資。此外，某些集團採購和競標流程，尤其是在美國以外的地區，限制了新設備的快速普及，並限制了價格的實現。

目標市場和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價

定性範圍

市場成長趨勢和限制因素、主要競爭對手的競爭分析和SWOT分析、併購、公司簡介和產品系列、FDA召回、顛覆性技術以及與胃食道逆流症相關的疾病概述

時期

基準年為2025年，預測期間為2026-2032年，歷史資料為2022-2024年。

數據來源

對行業領袖和醫生的初步調查、政府醫生數據、監管數據、私人醫院數據、進出口數據、iData Research 內部資料庫

方法

收入模型為單位乘以平均售價，並透過手術量、設備利用率以及按手術類別分類的更換或移除假設檢驗。

護理機構

醫院、專科中心和一些門診機構具備先進的內視鏡檢查和上消化道手術能力。

競爭分析

強生公司

強生公司的LINX逆流管理系統將一個由相互連接的鈦珠組成的軟性環置於食道下段，該鈦珠內部帶有磁性核心。吞嚥時，鈦珠會分離，而磁力則可有效防止逆流。 LINX系統吸引著那些尋求能夠維持正常食道解剖結構的機械解決方案的患者。其品牌知名度、臨床成功案例和清晰的作用機制，使其能夠持續獲得合格的患者。公司已擴大了其在外科產品分銷和培訓方面的規模，從而鞏固了其市場競爭力。

胃內解決方案

EndoGastric Solutions是第二大競爭對手，其EsophyX系統用於經口無切口胃包裹術。該公司透過密集的計畫、病患推廣和外科醫生培訓，擴大了其在美國的市場佔有率。其成長與醫療機構廣泛採用無切口手術密切相關，這些機構傾向於選擇恢復期短、創傷小的手術方案。儘管該公司正透過夥伴關係和培訓網路拓展其在美國以外的業務，但在美國市場仍然最為活躍。

瑞斯泰克

Restech在2025年排名第三。該公司於2018年收購了Mederi Therapeutics，從而獲得了Curon Medical的資產和Stretta射頻技術。 Stretta利用射頻能源重塑下食道括約肌和上腹部區域。 Restech透過將Stretta定位為無需植入的微創替代方案，在歐洲及其他地區不斷擴大市場佔有率。持續發布療效數據和嚴格的培訓體系為其穩步擴張提供了支持。

總體而言，競爭主要集中在少數幾家擁有強大臨床訊息和系統化培訓的專業供應商之間。成功與否取決於能否建立實證醫學基礎、拓展轉診管道，以及提供持續的術前術後護理，從而取得持久的療效。

科技與臨床趨勢

根據患者表現型調整治療方案正變得越來越普遍：醫生會評估疝氣的大小、食道炎的程度、動力和體重指數，並根據患者的解剖結構和症狀模式調整器械治療方法。

使用 pH 監測儀、電阻、測壓儀等進行標準化術前測試，將有助於改善選擇，並為支付方提供支援性文件。

術前和術後護理方案，包括飲食建議、吞嚥困難管理和藥物減量，可以提高患者滿意度並減少非計劃就診次數。

透過結構化的追蹤和檢驗的症狀評分來追蹤持久性，可以提高對長期結果和發表品質的信心。

內視鏡和腹腔鏡成像和視覺化技術的進步提高了器械放置和故障排除的準確性。

培訓和指導網路縮短了學習曲線，並擴大了有資格安全執行這些手術的醫生團隊。

該計劃的經濟重點在於病例捆綁、吞吐量和庫存管理，幫助中心證明其投資的合理性並保持可預測的利潤率。

地區

本期內容涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲等全球範圍。

調查方法附錄與簡稱

目錄

圖表清單

圖表列表

調查方法

全球關稅的影響

防回流裝置市場

• 摘要整理
  • 全球防回流裝置市場概覽
  • 競爭分析
  • 流程分段
  • 目標區域
• 介紹
• 手術次數
• 市場分析與預測
• 推動和阻礙因素
• 競爭市佔率分析

簡稱

The global anti-reflux device market was valued at nearly $199 million in 2025. The market is projected to grow at a compound annual growth rate of 16.2 percent, reaching over $567 million by 2032.

This report covers procedure-based device approaches for gastroesophageal reflux disease (GERD), including transoral incisionless fundoplication (TIF), transesophageal radiofrequency therapy, and the LINX Reflux Management System. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and it analyzes market drivers and limiters, recent mergers and acquisitions, and technology trends. It provides historical data to 2022 and forecasts to 2032.

The scope reflects how providers evaluate device-based GERD interventions relative to drug therapy and laparoscopic surgery across hospitals and specialty centers, as awareness rises, evidence grows, and patient preferences shift toward durable symptom relief with predictable recovery.

Market Overview

Anti-reflux devices address persistent GERD by reinforcing the barrier function at the gastroesophageal junction or by remodeling the lower esophageal sphincter. These interventions offer an option for patients who seek alternatives to long-term proton-pump inhibitor therapy or who remain symptomatic despite medication.

Growth is supported by three converging forces. First, product awareness has improved through targeted physician education and patient marketing by leading manufacturers. As more centers adopt TIF, radiofrequency therapy, and magnetic augmentation, procedural familiarity grows and referral pathways mature. Second, concerns about long-term PPI use have increased. Studies linking extended PPI therapy to hypomagnesemia and fracture risk have prompted many patients and physicians to reassess long-term medication plans. Third, obesity prevalence continues to rise, and central adiposity is associated with higher GERD symptom burden and reduced control with lifestyle changes alone. Together these forces support a steady increase in consultations for device-based therapy and a larger addressable market.

Adoption patterns vary by setting. Academic hospitals and high-volume GI centers often build structured reflux programs that include pre-procedure diagnostics, standardized patient selection, and coordinated follow-up. Community facilities tend to scale more gradually, focusing on one or two techniques that fit local skills and patient demand. Across settings, patient selection remains central. Clinicians weigh symptom severity, anatomy, hiatal hernia presence and size, motility status, and medication response to direct patients to the most suitable option.

Price and value dynamics reflect a balance between up-front device cost and downstream benefits. Providers emphasize procedural success rates, durability of symptom relief, reintervention rates, and the ability to reduce daily medication use. Payors and integrated systems focus on total cost of care, length of stay, and complication avoidance. As evidence accumulates and coding clarity improves, the market signals continued expansion from 2025 through 2032.

Market Drivers

Increased product awareness

Sustained marketing and education by leading companies have raised recognition of anti-reflux devices among surgeons, gastroenterologists, and patients. Peer-reviewed publications, conference workshops, and proctorship programs have improved visibility and confidence. As awareness rises, more candidates who are dissatisfied with long-term medication or who prefer a procedural solution are entering care pathways that include TIF, radiofrequency therapy, or magnetic augmentation. Surgeon familiarity increases procedure readiness and reduces perceived barriers to adoption.

Side effects of PPI medication

PPIs remain the first-line therapy for GERD, but concerns about long-term use are influencing treatment decisions. Extended exposure is associated with low serum magnesium levels, which can lead to irregular heartbeats, muscle spasms, and seizures. High-dose therapy is linked to increased risk of osteoporosis and fractures involving the wrist, spine, and hip. These safety signals do not eliminate the role of PPIs, but they prompt shared decision-making around duration and alternatives. As more patients seek durable symptom control without indefinite medication, device demand rises.

Increasing obesity

There is a well-documented relationship between central obesity and GERD symptom severity. As global obesity rates increase, the pool of patients with frequent reflux, nocturnal symptoms, and reduced medication response grows. Providers who already manage obesity-related comorbidities are expanding referral pathways to include device-based GERD treatments. As device credibility increases, a portion of this rising demand shifts from chronic medication toward procedural solutions, supporting total market growth.

Evidence and workflow maturation

Clinical protocols for patient selection, anesthesia, device sizing, and follow-up are improving. More centers standardize pre-procedure testing and use consistent patient-reported outcome measures. This leads to better case selection, more predictable results, and stronger satisfaction scores. As workflows stabilize, facilities are more willing to invest in staff training and capital support, which accelerates adoption.

Market Limiters

Pharmaceutical competition

Despite growing concerns, PPIs remain accessible and effective for many patients. Generics lower out-of-pocket costs and maintain adherence. New formulations and dosing strategies can reduce breakthrough symptoms, which delays or replaces referral for device therapy. If novel medications improve response in non-responders, device adoption may be tempered, especially in cost-sensitive markets where payors require medication optimization before authorizing a procedure.

Patient discomfort and expectations

All implant and energy-based procedures carry surgical risks and recovery considerations. Some patients report dysphagia, bloating, and chest discomfort after implantation or energy delivery. Difficulty swallowing and diet adjustments can affect early satisfaction. In a minority of cases, device removal occurs. The possibility of symptom persistence and the prospect of continuing daily medication even after a procedure can also reduce interest among patients who expect complete independence from drugs.

Follow-up medication usage

A share of patients will still need daily acid suppression after device therapy, although at lower doses or less frequently. For value-focused payors and patients, this reduces the perceived gap between medication-only care and procedure plus medication. Managing expectations and aligning on realistic outcomes is essential. Where communication is inconsistent, conversion rates fall and word-of-mouth slows.

Coverage variation and procurement limits

Coding clarity and coverage policies vary by region. In markets where reimbursement pathways are fragmented, hospitals face administrative hurdles that discourage program investment. In addition, certain group purchasing or tender processes limit rapid introduction of new devices and constrain price realization, particularly outside the United States.

Market Coverage and Data Scope

Quantitative coverage

Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.

Qualitative coverage

Market growth trends and limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews relevant to GERD.

Time frame

Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.

Data sources

Primary interviews with industry leaders and physicians, government physician data, regulatory data, hospital private data, import and export data, and the iData Research internal database.

Method note

Revenue is modeled from units multiplied by ASP, validated with procedure volumes, device utilization rates, and replacement or removal assumptions for each procedural category.

Care settings

Hospitals, specialty centers, and select ambulatory facilities with advanced endoscopy or foregut surgery capabilities.

Competitive Analysis

Johnson & Johnson

Johnson & Johnson offers the LINX Reflux Management System, a flexible ring of interlinked titanium beads with magnetic cores placed around the lower esophagus. The magnetic attraction resists reflux while allowing the beads to separate during swallowing. LINX appeals to patients seeking a mechanical solution that preserves normal anatomy. Its brand recognition, clinical track record, and clear mechanism of action support steady uptake in qualified candidates. The company's scale in surgical distribution and training strengthens its competitive position.

EndoGastric Solutions

EndoGastric Solutions is the second-leading competitor with the EsophyX system used for transoral incisionless fundoplication. The company has expanded market share through focused U.S. programs, patient outreach, and surgeon training. Growth is tied to broader adoption of incisionless approaches in centers that favor less invasive options with short recovery. Its presence outside the United States is growing through partnerships and training networks, but the company remains most active in the U.S. market.

Restech

Restech ranked third in 2025. The company acquired Mederi Therapeutics in 2018, which had previously acquired the Curon Medical assets and Stretta radiofrequency technology. Stretta delivers radiofrequency energy to remodel the lower esophageal sphincter and gastric cardia. Restech has increased share in Europe and other geographies by positioning Stretta as a minimally invasive alternative that can be performed without implants. Continued publication of outcomes data and disciplined training support gradual expansion.

Overall, the competitive field remains concentrated among a few specialized vendors with strong clinical messaging and structured training. Success depends on evidence generation, referral development, and consistent peri-procedural care to deliver durable outcomes.

Technology and Practice Trends

Procedure matching to patient phenotype is more common. Providers assess hernia size, esophagitis grade, motility, and BMI to align the device approach with anatomy and symptom pattern.

Standardized pre-procedure testing using pH monitoring, impedance, and manometry improves selection and supports payor documentation.

Peri-procedural pathways that include diet coaching, dysphagia management, and medication tapering improve satisfaction and reduce unplanned visits.

Durability tracking with structured follow-up and validated symptom scores builds confidence in long-term outcomes and publication quality.

Imaging and visualization advances in endoscopy and laparoscopy improve accuracy in device placement and troubleshooting.

Training and proctoring networks shorten the learning curve and expand the number of credentialed physicians who can perform these procedures safely.

Program economics emphasize case bundling, throughput, and inventory control, which helps centers justify investment and maintain predictable margins.

Geography

This edition provides global coverage for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa

Methodology Appendix and Acronym Glossary

Why This Report

Where are the largest and fastest growing opportunities within anti-reflux devices and how will volumes evolve as awareness and coverage expand

How do PPI safety concerns and obesity trends translate into device referrals and long-term demand

What are the key barriers to adoption, including patient discomfort, continued medication use after procedures, and variable coverage policies

Which devices are best suited for specific patient profiles and how should centers structure reflux programs to improve throughput and outcomes

How do leading companies Johnson & Johnson, EndoGastric Solutions, and Restech position their portfolios and training to defend and expand share

What are the pricing and procurement dynamics that shape ASPs, from tenders to payor approvals, and how do facilities build a sustainable business case

The Global Anti-Reflux Device Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, align portfolio strategy with patient selection pathways, and plan commercial execution that matches program economics and referral behavior.

TABLE OF CONTENT

Table Of Contents

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Anti-Reflux Device Market

• 13.1 Executive Summary
  • 13.1.1 Global Anti-Reflux Device Market Overview
  • 13.1.2 Competitive Analysis
  • 13.1.3 Procedure Segmentation
  • 13.1.4 Regions Included
• 13.2 Introduction
• 13.3 Procedure Numbers
• 13.4 Market Analysis And Forecast
• 13.5 Drivers And Limiters
  • 13.5.1 Market Drivers
  • 13.5.2 Market Limiters
• 13.6 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 13-1: Anti-Reflux Device Market, Global, 2025 & 2032
• Chart 13-2: Anti-Reflux Device Procedures, Global, 2025
• Chart 13-3: Anti-Reflux Device Implants Procedures by Region, Global, 2022 - 2032
• Chart 13-4: Anti-Reflux Device Market, Global, 2022 - 2032
• Chart 13-5: Anti-Reflux Device Market by Region, Global, 2022 - 2032
• Chart 13-6: Leading Competitors, Anti-Reflux Device Market, Global, 2025

LIST OF FIGURES

• Figure 13-1: Anti-Reflux Device Procedure Segmentation
• Figure 13-2: Anti-Reflux Device Regions Covered, Global (1 of 2)
• Figure 13-3: Anti-Reflux Device Regions Covered, Global (2 of 2)
• Figure 13-4: Anti-Reflux Device Implants Procedures by Region, Global, 2022 - 2032
• Figure 13-5: Anti-Reflux Device Implants Procedures by Country, North America, 2022 - 2032
• Figure 13-6: Anti-Reflux Device Implants Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-7: Anti-Reflux Device Implants Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-8: Anti-Reflux Device Implants Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-9: Anti-Reflux Device Implants Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-10: Anti-Reflux Device Implants Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-11: Anti-Reflux Device Implants Procedures by Country, Middle East, 2022 - 2032
• Figure 13-12: Anti-Reflux Device Implants Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-13: Anti-Reflux Device Implants Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-14: Anti-Reflux Device Implants Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-15: Anti-Reflux Device Implants Procedures by Country, Africa, 2022 - 2032
• Figure 13-16: Anti-Reflux Device Market, Global, 2022 - 2032
• Figure 13-17: Anti-Reflux Device Market by Region, Global, 2022 - 2032
• Figure 13-18: Units Sold by Region, Anti-Reflux Device Market, Global, 2022 - 2032
• Figure 13-19: Average Selling Price by Region, Anti-Reflux Device Market, Global, 2022 - 2032 (US$)
• Figure 13-20: Market Value by Region, Anti-Reflux Device Market, Global, 2022 - 2032 (US$M)
• Figure 13-21: Leading Competitors, Anti-Reflux Device Market, Global, 2025